Show simple item record

Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study

dc.contributor.authorChung, HC
dc.contributor.authorBang, YJ
dc.contributor.authorTabernero, J
dc.contributor.authorVan Cutsem, E
dc.contributor.authorFuchs, CS
dc.contributor.authorWyrwicz, L
dc.contributor.authorLee, KW
dc.contributor.authorKudaba, I
dc.contributor.authorGarrido, M
dc.contributor.authorCastro, H
dc.contributor.authorMansoor, Was
dc.contributor.authorBraghiroli, MI
dc.contributor.authorGoekkurt, E
dc.contributor.authorChao, J
dc.contributor.authorWainberg, ZA
dc.contributor.authorKher, U
dc.contributor.authorShah, S
dc.contributor.authorShitara, K
dc.date.accessioned2020-01-29T15:17:52Z
dc.date.available2020-01-29T15:17:52Z
dc.date.issued2019en
dc.identifier.citationChung HC, Bang YJ, Tabernero J, Van Cutsem E, Fuchs CS, Wyrwicz L, et al. Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study. Annals of Oncology. 2019;30:ix43-ix4.en
dc.identifier.doi10.1093/annonc/mdz422.003en
dc.identifier.urihttp://hdl.handle.net/10541/622695
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz422.003en
dc.titlePembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Koreaen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record